Medical Description
Antidiabetic combination therapy consisting of a sulfonylurea agent and a thiazolidinedione agent used in the treatment of type 2 diabetes mellitus.
Indication & Usage
Type 2 diabetes mellitus: Oral: A-Initial dose should be based on current dose of pioglitazone and/or sulfonylurea: 1-In case of patients inadequately controlled on glimepiride alone: Initial dose: Pioglitazone 30 mg/glimepiride 2 mg or pioglitazone 30 mg/glimepiride 4 mg once daily. 2-In case of patients inadequately controlled on pioglitazone alone: Initial dose: Pioglitazone 30 mg/glimepiride 2 mg once daily. 3-In case of patients currently on sulfonylurea monotherapy (other than glimepiride) or switching from combination therapy of pioglitazone plus a sulfonylurea (other than glimepiride): Initial: Pioglitazone 30 mg/glimepiride 2 mg once daily. 4-In case of patients with systolic dysfunction: Initiate only after patient has been safely titrated to 30 mg of pioglitazone. Initial dose: Pioglitazone 30 mg/glimepiride 2 mg once daily. B-Dosage adjustment: Dosage may be increased up to a maximum dose of pioglitazone 45 mg/glimepiride 8 mg once daily based on effectiveness and tolerability.
Active Ingredients
Pioglitazone
Glimepiride